|Bid||0.5023 x 1200|
|Ask||0.5499 x 900|
|Day's Range||0.5323 - 0.5598|
|52 Week Range||0.3750 - 2.5000|
|Beta (3Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Atyr Pharma (LIFE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The San Diego-based company said it had a loss of 21 cents per share. For the year, the company reported that its loss narrowed to $34.5 million, or $1.15 per share. In the final minutes of trading on ...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
On a per-share basis, the San Diego-based company said it had a loss of 24 cents. In the final minutes of trading on Tuesday, the company's shares hit 55 cents. A year ago, they were trading at $3.65. ...
On a per-share basis, the San Diego-based company said it had a loss of 35 cents. In the final minutes of trading on Tuesday, the company's shares hit 66 cents. A year ago, they were trading at $3.25. ...